Nuveen Asset Management, LLC - SYNDAX PHARMACEUTICALS INC ownership

SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 74 filers reported holding SYNDAX PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.

Quarter-by-quarter ownership
Nuveen Asset Management, LLC ownership history of SYNDAX PHARMACEUTICALS INC
ValueSharesWeighting
Q2 2024$11,423,179
+22.2%
556,414
+41.7%
0.00%0.0%
Q1 2024$9,345,926
-30.7%
392,686
-37.1%
0.00%
-25.0%
Q4 2023$13,484,856
+435.5%
624,010
+259.8%
0.00%
+300.0%
Q3 2023$2,518,334
-25.2%
173,439
+7.8%
0.00%0.0%
Q2 2023$3,368,621
+105367.2%
160,947
+6.4%
0.00%0.0%
Q1 2023$3,194
-13.3%
151,237
+4.4%
0.00%0.0%
Q4 2022$3,686
-99.9%
144,862
-12.7%
0.00%
-50.0%
Q3 2022$3,986,000
+24.9%
165,877
+0.0%
0.00%
+100.0%
Q2 2022$3,191,000
+15.1%
165,842
+1.4%
0.00%0.0%
Q1 2022$2,773,000
-5.4%
163,590
-0.2%
0.00%0.0%
Q4 2021$2,932,000
-15.2%
163,861
-6.2%
0.00%0.0%
Q3 2021$3,458,000
-7.2%
174,670
-19.5%
0.00%0.0%
Q2 2021$3,725,000
+20.6%
216,914
+57.0%
0.00%0.0%
Q1 2021$3,090,000
-11.1%
138,191
-11.6%
0.00%0.0%
Q4 2020$3,477,000
+26.2%
156,338
-16.2%
0.00%0.0%
Q3 2020$2,755,000
+58.4%
186,641
+59.1%
0.00%0.0%
Q2 2020$1,739,000
+111.0%
117,303
+56.3%
0.00%
Q1 2020$824,000
+5.2%
75,037
-15.8%
0.00%
Q4 2019$783,000
-29.6%
89,156
-40.2%
0.00%
Q3 2019$1,113,000
+9.4%
148,988
+36.4%
0.00%
Q2 2019$1,017,000109,2320.00%
Other shareholders
SYNDAX PHARMACEUTICALS INC shareholders Q2 2019
NameSharesValueWeighting ↓
MPM ASSET MANAGEMENT LLC 2,168,691$30,297,00013.16%
Boxer Capital, LLC 234,220$3,272,0000.78%
SPHERA FUNDS MANAGEMENT LTD. 296,310$4,139,0000.70%
Ghost Tree Capital, LLC 200,000$2,794,0000.58%
Eventide Asset Management 225,000$3,143,0000.20%
Vident Investment Advisory, LLC 103,558$1,447,0000.12%
J. Goldman & Co LP 147,181$2,056,0000.11%
TIVERTON ASSET MANAGEMENT LLC 137,732$1,924,0000.10%
Crestline Management, LP 55,368$773,0000.10%
Tekla Capital Management LLC 200,000$2,794,0000.10%
View complete list of SYNDAX PHARMACEUTICALS INC shareholders